Instil Bio (TIL) Stock Price, News & Analysis

Company Overview

Instil Bio plc is a clinical‐stage biotechnology company focused on the discovery, development and delivery of off‐the‐shelf cell therapies for cancer and other serious diseases. The company’s proprietary Instinct Platform leverages high‐parameter single‐cell multiomics, machine learning and immunological screening to identify and engineer natural killer (NK) and T cell products with enhanced potency, persistence and safety. Instil Bio’s technology backbone is designed to accelerate the translation of novel cellular candidates through in vitro and in vivo models, providing a systematic approach to next‐generation immuno‐oncology therapies.

The company’s pipeline includes lead programs such as INB‐101, an allogeneic, engineered NK cell therapy currently in Phase 1 clinical evaluation for refractory solid tumors, and a series of follow‐on candidates collectively known as the INB‐200 series. These programs employ targeted genetic modifications to improve tumor antigen recognition, enhance cell trafficking and resist the immunosuppressive tumor microenvironment. Beyond oncology, Instil Bio is exploring applications in rare hematological disorders and infectious diseases by adapting its platform to different immune cell types and therapeutic modalities.

Founded in 2020 and headquartered in the United Kingdom and United States, Instil Bio combines multidisciplinary expertise in immunology, genomics and cell therapy manufacturing. The company completed its Nasdaq listing via a business combination in 2022, positioning it to advance multiple clinical programs while expanding its research and manufacturing capabilities. Led by a management team with deep experience in biotech R&D and commercialization, Instil Bio aims to establish a new standard for the discovery and development of engineered cell therapies on a global scale.

Key Stats

• Today's Range: $7.54 to $7.69
• 50-Day Range: $7.12 to $7.86
• 52-Week Range: $5.67 to $33.83
• Volume: 685 shs
• Average Volume: 55,467 shs
• Market Capitalization: $51.12 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $66.00
• Consensus Rating: Reduce

Instil Bio Stock Analysis - MarketRank™

Instil Bio scored higher than 55% of companies evaluated by MarketBeat, and ranked 490th out of 917 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.0 / 5
• Analyst Rating: Reduce

Consensus Rating

Instil Bio has received a consensus rating of Reduce. The company's average rating score is 1.67, and is based on no strong buy ratings, no buy ratings, 2 hold ratings, and 1 sell rating.

Upside Potential

Instil Bio has a consensus price target of $66.00, representing about 757.1% upside from its current price of $7.70.

Amount of Analyst Coverage

Instil Bio has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Instil Bio is -1.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Instil Bio is -1.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Instil Bio has a P/B Ratio of 0.46. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.91% of the float of Instil Bio has been sold short.

Short Interest Ratio / Days to Cover

Instil Bio has a short interest ratio ("days to cover") of 21.5, which indicates bearish sentiment.

Change versus previous month

Short interest in Instil Bio has recently decreased by 6.79%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Instil Bio does not currently pay a dividend.

Dividend Growth

Instil Bio does not have a long track record of dividend growth.

News and Social Media

• Score: 4.0 / 5
• News Sentiment: N/A

News Sentiment

Instil Bio has a news sentiment score of 1.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.98 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Instil Bio this week, compared to 1 article on an average week.

Search Interest

2 people have searched for TIL on MarketBeat in the last 30 days.

MarketBeat Follows

1 people have added Instil Bio to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.4 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Instil Bio insiders have not sold or bought any company stock.

Percentage Held by Insiders

47.00% of the stock of Instil Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

60.56% of the stock of Instil Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/13/2026
• Today: 8/31/2026
• Next Earnings (Estimated): 11/16/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:TIL
• CIK: 1625584
• Web: www.tillcap.com
• Phone: 972-499-3350
• Fax: N/A
• Employees: 410
• Year Founded: 2008

Price Target and Rating

• Average Price Target for Instil Bio: $66.00
• High Price Target: $125.00
• Low Price Target: $7.00
• Potential Upside/Downside: +775.3%
• Consensus Rating: Reduce
• Rating Score (0-4): 1.67
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($4.47)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$71.37 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -26.78%
• Return on Assets: -14.89%

Debt

• Debt-to-Equity Ratio: 0.79
• Current Ratio: 21.67
• Quick Ratio: 21.67

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $16.79 per share
• Price / Book: 0.45

Miscellaneous

• Outstanding Shares: 6,780,000
• Free Float: 3,594,000
• Market Cap: $51.12 million
• Optionable: No Data
• Beta: 1.94